ProMIS Neurosciences Inc. SEDAR Filings

Results 2026-05-28

Open PDF

Interim MD&A - English.pdf

Results 2026-05-28

Open PDF

Interim financial statements/report – English.pdf

News 2026-05-28

Open PDF

ProMIS Neurosciences to Participate in Upcoming Conferences in June

News release - English.pdf

Results 2026-05-12

Open PDF

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

News release - English.pdf

Results 2026-03-25 Financials

Annual report on form 10-K - English.pdf

Results 2026-03-25 Financials

Open PDF

Annual MD&A - English.pdf

Results 2026-03-25 Financials

Open PDF

Audited annual financial statements – English.pdf

Results 2026-03-25

Open PDF

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

News release - English.pdf

News 2026-03-18

Offering material - English.pdf

News 2026-03-18

Offering material - English.pdf

News 2026-03-18

Open PDF

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

News release - English.pdf

News 2026-02-04

Open PDF

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

News release - English.pdf

Transactions 2026-01-30 Financing

Open PDF

PROMIS NEUROSCIENCES INC. Announces Pricing of US$75 Million Offering

Material change report - English.pdf

Transactions 2026-01-30 Financing

Open PDF

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

News release - English.pdf

News 2025-12-18

Open PDF

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

News release - English.pdf

News 2025-12-10

Open PDF

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

News release - English.pdf

News 2025-12-01

Open PDF

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

News release - English.pdf

News 2025-12-01

Open PDF

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

News release - English.pdf

Results 2025-11-24 Returns

Open PDF

ProMIS Neurosciences Announces Reverse Stock Split

News release - English.pdf

Results 2025-11-12 Financials

Open PDF

Interim MD&A - English.pdf